Completed
PHASE4
INTERVENTIONAL
NCT03985384
Semaglutide Treatment On Coronary Progression
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this research study is to see the effect of the diabetes medicine Semaglutide on a condition called atherosclerosis. Atherosclerosis is a narrowing, blockage, or hardening of the arteries due to a build up of calcium. This study will look specifically at the arteries involving the heart.
Detailed Description
To determine the effects of semaglutide therapy on the morphology and composition of non-calcified coronary atherosclerotic plaque (NCP), including the progression of plaque volume.
Interventions
Name:
Semaglutide 2 MG/1.5 ML Subcutaneous Solution
Type:
DRUG
Description:
Semaglutide 2 MG/1.5 ML Subcutaneous Solution
Name:
Placebo
Type:
DRUG
Description:
Placebo 1.5 ml, pen-injector for SC injection.
Primary Outcomes
Measure:
Rate of change in non-calcified plaque volume
TimeFrame:
12 months
Description:
Rate of change in non-calcified plaque volume
Trial Information
NCT ID
NCT03985384
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE4
Sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Last Updated
December 15, 2025